Related Experiment Videos
DNA vaccines to attack cancer
Freda K Stevenson1, Christian H Ottensmeier, Peter Johnson
1Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton SO16 6YD, UK. fs@soton.ac.uk
Summary
DNA vaccination delivers antigens to enhance immune responses against cancer. This strategy uses fused microbial proteins to activate T helper cells, leading to potent antitumor immunity and potential therapeutic applications in clinical trials.
Area of Science:
- Immunology
- Molecular Biology
- Vaccine Development
Background:
- DNA vaccination enables antigen delivery via multiple antigen-presenting pathways.
- Modifying DNA construct design can tailor immune responses for therapeutic applications.
- Overcoming immune tolerance is crucial for effective cancer immunotherapy.
Purpose of the Study:
- To develop DNA vaccine strategies for activating antitumor immunity, particularly against cancer.
- To leverage T helper cell responses for enhanced antibody and T cell effector functions against tumor antigens.
- To investigate methods for overcoming immune tolerance in cancer patients.
Main Methods:
- Fusing tumor-derived sequences with genes encoding microbial proteins to elicit linked T cell help.
- Designing epitope-specific DNA vaccines to induce antitumor CD8(+) T cell responses.
- Utilizing physical methods like electroporation to enhance antigen expression.
Main Results:
- The strategy successfully engaged T helper cells, inducing antibodies against cell-surface tumor antigens.
- Epitope-specific DNA vaccination demonstrated powerful antitumor attack and activated immunity in tolerized repertoires.
- Preclinical vaccine designs are in clinical trials, showing immune responses against both tumor and microbial antigens.
Conclusions:
- DNA vaccination is a highly efficient method for priming antitumor immunity.
- Boosting may be improved by increasing antigen expression, potentially via physical methods.
- This approach holds promise for targeting a wide range of cancers and activating immune responses in tolerized patients.